20:52:17 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-11-23 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-04-08 Ordinarie utdelning DANCAN 0.00 DKK
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-08-27 09:00:00

COPENHAGEN, Denmark, 28 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby today releases its results for the period 1 April - 30 June 2021 (the "period"). The Q2-2021 report is available as an attached document to this press release and on www.dancann.com.

Key figures Q2 2021

KDKK 01/04/21 01/04/20 30/06/20 01/01/21 30/06/21 01/01/20 30/06/20
30/06/21
Net sales 0 0 0 0
Operating -3,771 -1,237 -6,362 -1,499
profit
(EBIT)
Result per -0.14 -1.8 -0.22 -4.47
share (DKK)
Equity 0.89 0.96 0.89 -0.42
ratio

Number of shares on the 01/01/20: 1
Number of shares on the 08/04/20: 175,760
Number of shares on the 26/06/20: 14,060,800
Number of shares on the 02/10/20: 20,730,800

CEO Jeppe Krog Rasmussen, comments:

"Like Q1 this quarter has been extremely eventful. Following DanCann Pharma's IPO in November 2020, where we received a capital injection that made it possible to realize our ambitious goals, things have only moved in one direction. Forward. We have strengthened our organization with the right competencies in production, administration, and management. At the same time, we have succeeded in attracting the strong industry personality Christian Carlsen to our Board of Directors.

In our production facilities BIOTECH PHARM1, we pressed the start button in April and started the selection of genetics. After lots of tests, the first batch was put into production, and eight weeks later we were able to celebrate the first of 13 training harvests, which will be completed, dried, and analyzed throughout the rest of 2021. It is very positive that both the consumption of fertilizer, nutrients and water is significantly below expectations.

At our annual general meeting, it was decided that later in the year, we would have the opportunity to implement another capital increase, this time through a private placement. The decision was confirmed at an extraordinary general meeting at the end of July and immediately afterwards DanCann Pharma realized approx. DKK 16.3 million from a consortium of private investors in combination with a loan option of around DKK 11 million.

The extra capital will be used to significantly expand our production facilities. We are currently experiencing a huge demand for cannabis biomaterial, so by investing further, we will be able to hit the market - specifically the German one - both faster and with greater effect."

Highlights during the period

DanCann Pharma A/S issues warrants to the executive management team TUE, APR 06, 2021
COPENHAGEN, Denmark, 06 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby today announces that the Board of Directors has issued 1,017,147 warrants to the executive management team in DanCann Pharma with a subscription rate of DKK 3.3327.

DanCann Pharma A/S publishes Annual Report 2020 WED, APR 07, 2021 COPENHAGEN, Denmark, 07 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") announce that The Board of Directors and the Chief Executive Officer of DanCann Pharma hereby publishes the annual report of the year 2020. The annual report including the auditor's report is available in this press release and on the website of DanCann Pharma.

DanCann Pharma A/S appoints Helle Bjerregaard as Head of Quality FRI, APR 16, 2021
COPENHAGEN, Denmark, 16 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Helle Bjerregaard. Helle Bjerregaard has been appointed as Head of Quality (HOQ) at DanCann Pharma A/S.

DanCann Pharma A/S has pressed the start button in BIOTECH PHARM1 THU, APR 22, 2021
COPENHAGEN, Denmark, 22 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce that following pre-selective operations around the Company's genetics in BIOTECH PHARM1 ("the Facility"), the Company today begins its first real operations and first cycles in its new Facility.

DanCann Pharma A/S: Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial MON, APR 26, 2021
COPENHAGEN, Denmark, 26 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma") hereby on behalf of Tetra Bio-Pharma Inc. ("Tetra"), announce an update on their U.S. REBORN1 Clinical Trial.

DanCann Pharma A/S: Market update for penetration of the Danish market, cf. the Danish Pilot Programme with medical cannabis MON, APR 26, 2021
COPENHAGEN, Denmark, 26 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby provides an update on its market penetration of the Danish market, cf. the Danish Pilot Programme with medical cannabis.

DanCann Pharma A/S Annual General Meeting 2021 and decisions by the Board of Directors WED, APR 28, 2021
MINUTES OF ANNUAL GENERAL MEETING held in DanCann Pharma A/S, business reg. no. 39 42 60 05.

DanCann Pharma A/S issues warrants to the Board of Directors WED, APR 28, 2021 COPENHAGEN, Denmark, 28 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby today announces that DanCann Pharma has issued 300,000 warrants to the Board of Directors in DanCann Pharma with a subscription rate of DKK 3.8993.

 

DanCann Pharma A/S have signed a definitive distribution agreement with Tetra Bio-Pharma Inc. for the exclusive distribution of Reduvo™ Adversa® and Qixleef™ in Scandinavia and Germany WED, MAY 05, 2021
COPENHAGEN, Denmark, 5 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the signing of an agreement with Canadian Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) ("Tetra") concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and Qixleef™ in Denmark, Norway, Sweden, Finland, and Germany.

DanCann Pharma A/S: Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial FRI, MAY 07, 2021
COPENHAGEN, Denmark, 7 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma") hereby on behalf of Tetra Bio-Pharma Inc. ("Tetra"), announce the start of the RE-BORN1© clinical trial. This trial is designed to evaluate the effect of the company's inhaled proprietary drug formulation, QIXLEEF™, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer. QIXLEEF™ is a botanical drug product with a "fixed ratio" of THC and CBD and is inhaled through a Class 2 medical device vaporizer.

DanCann Pharma A/S: Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain TUE, MAY 11, 2021
COPENHAGEN, Denmark, 11 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma") hereby on behalf of Tetra Bio-Pharma Inc. ("Tetra" or "the Company"), announce the acceleration of a revolutionary Phase 2 clinical trial, PLENITUDE©, to evaluate the safety and efficacy of the investigational cannabis medicine, QIXLEEF™, for use in managing uncontrolled pain in patients with advanced cancer.

DanCann Pharma A/S: The future is secured: The Pilot Programme has been made permanent WED, MAY 26, 2021
COPENHAGEN, Denmark, 26 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby happily announce that the Danish government with the support from other political parties have entered into an agreement on 25 May 2021 to continue The Pilot Programme with medical cannabis.

DanCann Pharma A/S publishes Q1-2021 report FRI, MAY 28, 2021
COPENHAGEN, Denmark, 28 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby today releases its results for the period 1 January - 31 March 2021 (the "period"). The Q1-2021 report is now available

Impressive growth rate at DanCann Pharma A/S TUE, JUN 15, 2021
COPENHAGEN, Denmark, 15 June 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce, that the development of the mother plant genetics in BIOTECH-PHARM1, the production facilities inaugurated in April, exceeds the Company's expectations.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com